Mid-Atlantic Microbial Pathogenesis Meeting 2022
Mid-Atlantic Microbial Pathogenesis Meeting 2022
批准号:
10504721
负责人:
Robert K Ernst
金额:
$1.34万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2023-01-31
中文摘要
摘要
第11届中大西洋微生物发病机制会议(MAMPM)将于2022年2月13日至15日在
Wintergreen Resort and Conference Center附近的夏洛茨维尔,弗吉尼亚州. MAMPM的目的是
促进中大西洋微生物发病机理研究人员之间的交流和合作(NC,
VA,MD,DC,WV和DE,尽管来自12个州的研究人员现在正在参加)。许多FDA资助的
研究对人类健康具有重要意义的病原体的毒力机制的研究人员在这
地理区域,并参加了多个MAMPM。MAMPM的主要目标之一是提供
学生,博士后研究员和初级教师有机会向知识渊博的
观众,专注于这一学科,在一个学院,但科学严谨的环境。会议
MAMPM是青年科学家专业发展的形成经验,
仍然是本次会议最吸引人和得到积极评价的方面之一。前十名
会议在冬青度假村会议中心举行,该中心位于市中心,
一流的设施和专业的会议工作人员。在我们的最后一次会议上(2019年),我们实现了最大限度的
第一次报名(201人)。
MAMPM 2022由组委会安排,由当前,未来和过去两个组成
会议椅绝大多数演讲者是研究生、博士后和大三学生。
由四位国际知名的主讲人介绍每一节课。Tod默克尔博士(FDA
工作人员科学家),弗吉尼亚米勒(弗吉尼亚州),利诺德勒(华盛顿州立大学)和马丁Wiedmann(康奈尔大学)是MAMPM
2022主题演讲此外,还将举办两次参与人数众多的互动海报会议,
让所有与会者有机会面对面地介绍和讨论他们的工作。MAMPM 2022将是
通过专业出版物、社交媒体帖子和直接邮寄广告进行宣传
(实物和电子邮件)发送给学术机构、政府和私人实验室的相关部门
在该地区和当地的美国微生物学学会分支机构的成员,
地区一个专门的网站(http://mampm.org/)对会议进行宣传,并提供必要的信息。
注册所需的信息和表格。MAMPM还大力支持性/性别多样性,
种族/民族、年龄和残疾状况。阿什利海恩斯和卡莱塔佩奇-安德森博士将担任
多样性大使,以加强代表性不足的群体的参与。MAMPM 2022将展出
MAMPM推进多样性倡议,由不同组成的小组讨论职业转型。
最后,在MAMPM上展示的研究与FDA的使命高度相关,特别是在开发
新型疫苗、人类疾病的诊断和治疗平台,以及保护公众
抵御新出现的传染病的威胁。
英文摘要
ABSTRACT
The 11th Mid-Atlantic Microbial Pathogenesis Meeting (MAMPM) will be held February 13-15, 2022 at
Wintergreen Resort and Conference Center near Charlottesville, Virginia. The purpose of the MAMPM is to
foster communication and collaboration among microbial pathogenesis researchers in the Mid-Atlantic (NC,
VA, MD, DC, WV, and DE, though researchers from 12 states are now attending). Numerous FDA-funded
investigators studying the virulence mechanisms of pathogens of importance to human health are in this
geographic region and have participated in multiple MAMPMs. One of MAMPM’s key goals is to provide
students, postdoctoral fellows, and junior faculty with the opportunity to present their work to a knowledgeable
audience, focused on this discipline, in a collegial yet scientifically rigorous environment. Conference
evaluations consistently MAMPM is a formative experience for young scientists’ professional development and
remains one of the most appealing, and positively evaluated, aspects of this conference. All ten previous
meetings have been held at Wintergreen Resort Conference Center, which features a central location,
excellent facilities, and a professional conference staff. At our last meeting (2019), we achieved maximum
registration (201 attendees) for the first time.
MAMPM 2022 is arranged by the Organizing Committee, comprised of the current, future, and past two
conference chairs. The vast majority of the presenters are graduate students, postdoctoral fellows, and junior
faculty with four internationally renowned keynote speakers introduce each session. Drs. Tod Merkel (FDA
staff scientist), Virginia Miller (UNC), Leigh Knodler (WSU), and Martin Wiedmann (Cornell) are the MAMPM
2022 keynote speakers. In addition, two highly attended and interactive poster sessions will be provided to
allow the opportunity for all participants to present and discuss their work face-to-face. MAMPM 2022 will be
publicized through advertisements in professional publications, social media posts, and direct mailings
(physical and email) to relevant departments at academic institutions, government and private laboratories
within the region and to members of the local American Society for Microbiology branches that serve this
region. A dedicated website (http://mampm.org/) publicizes the meeting and provides the necessary
information and forms required for registration. MAMPM also strongly supports diversity in sex/gender,
race/ethnicity, age, and disability status. Drs. Ashley Haines and Carleitta Paige-Anderson will serve as
Diversity Ambassadors to enhance participation from underrepresented groups. MAMPM 2022 will feature the
MAMPM Advancing Diversity Initiative, with panels of diverse composition to discuss career transitions.
Finally, research presented at MAMPM is highly relevant to FDA's mission, particularly in the development
of novel vaccines, diagnostic and treatment platforms for the human diseases, and protection the public
against the threats of emerging infectious diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
-
批准号:10722599
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2023
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10116273
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10356152
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
MS Diagnostic Bacterial Identification Library
-
批准号:10570981
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2020
-
负责人:Robert K Ernst
-
依托单位:
Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants
-
批准号:9753900
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2016
-
负责人:Robert K Ernst
-
依托单位:
MS diagnostic bacterial identification library
-
批准号:8722128
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2014
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8650788
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
-
批准号:8511015
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8675799
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
-
批准号:8584054
-
项目类别:
-
资助金额:$18.04万
-
财政年份:2013
-
负责人:Robert K Ernst
-
依托单位:
Bacterial Lipopolysaccharide Structure
-
批准号:7637607
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2008
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7476478
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7681139
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7911766
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2001
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7147812
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
Pseudomonas aeruginosa lipid A
-
批准号:7254098
-
项目类别:
-
资助金额:$34.08万
-
财政年份:2000
-
负责人:Robert K Ernst
-
依托单位:
海外基金